文献速递肝病

Emricasan用于预防NASH相关失代偿期肝硬化患者新发失代偿事件

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2020-10-08

这项双盲、安慰剂对照研究将217例失代偿性NASH肝硬化患者按1:1:1随机分配至Emricasan 5 mg、25 mg或安慰剂组,主要终点为全因死亡、新发失代偿事件或MELD-Na评分增加≥4分。结果显示两个Emricasan组与安慰剂组事件发生率均无差异,HR分别为1.02(95%CI 0.59-1.77;p=0.94)和1.28(95%CI 0.75-2.21;p=0.37),Emricasan安全但无效。

要点

  • Emricasan 5 mg和25 mg组与安慰剂组事件发生率无差异。
  • MELD-Na评分进展是最常见结局,Emricasan对MELD-Na、INR、总胆红素、白蛋白或Child-Pugh评分无显著影响。
  • Emricasan总体安全且耐受良好,但对失代偿性NASH肝硬化无效。

核心结论

  • Emricasan对失代偿性NASH肝硬化治疗安全但无效,但该研究可能为未来失代偿性NASH肝硬化的临床试验设计和实施提供指导。

研究设计与样本

  • 双盲、安慰剂对照研究,随机分配217例失代偿性NASH肝硬化患者按1:1:1至Emricasan 5 mg、25 mg或安慰剂组,按失代偿状态和基线MELD-Na评分分层。

主要发现

  • Emricasan 5 mg组与安慰剂组事件发生率无差异,HR为1.02(95%CI 0.59-1.77;p=0.94)。
  • Emricasan 25 mg组与安慰剂组事件发生率无差异,HR为1.28(95%CI 0.75-2.21;p=0.37)。
  • MELD-Na评分进展是最常见结局。
  • Emricasan对MELD-Na评分、国际标准化比值、总血清胆红素、白蛋白水平或Child-Pugh评分无显著影响。
  • Emricasan总体安全且耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hepatocellular carcinoma. Emricasan is a pan-caspase inhibitor that inhibits excessive apoptosis and inflammation; it has also been shown to decrease portal pressure and improve synthetic function in mice with carbon tetrachloride-induced cirrhosis. METHODS: This double-blind, placebo-controlled study randomized 217 individuals with decompensated NASH cirrhosis 1:1:1 to emricasan (5 mg or 25 mg) or placebo. Patients were stratified by decompensation status and baseline model for end-stage liver disease-sodium (MELD-Na) score. The primary endpoint comprised all-cause mortality, a new decompensation event (new or recurrent variceal hemorrhage, new ascites requiring diuretics, new unprecipitated hepatic encephalopathy ≥grade 2, hepatorenal syndrome, spontaneous bacterial peritonitis), or an increase in MELD-Na score ≥4 points. RESULTS: There was no difference in event rates between either of the emricasan treatment groups and placebo, with hazard ratios of 1.02 (95% CI 0.59-1.77; p = 0.94) and 1.28 (95% CI 0.75-2.21; p = 0.37) for 5 mg and 25 mg of emricasan, respectively. MELD-Na score progression was the most common outcome. There was no significant effect of emricasan treatment on MELD-Na score, international normalized ratio, total serum bilirubin, albumin level or Child-Pugh score. Emricasan was generally safe and well-tolerated. CONCLUSIONS: Emricasan was safe but ineffective for the treatment of decompensated NASH cirrhosis. However, this study may guide the design and conduct of future clinical trials in decompensated NASH cirrhosis. LAY SUMMARY: Patients with decompensated cirrhosis related to non-alcoholic steatohepatitis are at high risk of additional decompensation events and death. Post hoc analyses in previous pilot studies suggested that emricasan might improve portal hypertension and liver function. In this larger randomized study, emricasan did not decrease the number of decompensation events or improve liver function in patients with a history of decompensated cirrhosis related to non-alcoholic steatohepatitis. CLINICALTRIALS. GOV IDENTIFIER: NCT03205345.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Frenette C, Kayali Z, Mena E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2020. PMID: 33038432. doi:10.1016/j.jhep.2020.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。